09/06/21 -"Our target price hike is largely attributable to an increase in our peer-based valuations, as we have factored in a premium of 20% vs none earlier. We believe, given the recovery from the quality ..."
Pages
59
Language
English
Published on
09/06/21
You may also be interested by these reports :
03/02/26
Sartorius Stedim’s operations recovered well in FY25, driven primarily by high-margin consumables. Positive volume and mix effects expanded ...
03/02/26
Demant’s 2025 figures slightly exceeded estimates, driven by growth in Hearing Care and Diagnostics, particularly towards the year-end. However, ...
28/01/26
Getinge reported a soft Q4, with net sales and adjusted EBITA missing expectations and organic growth slowing to 1.2%. Order momentum also eased, ...
22/01/26
CZM’s Q1 FY 2025-26 preliminary release fell short of market expectations. Sales and profitability were adversely affected by both external and ...